All questions
Specific populations: Trulicity (dulaglutide) in type 2 diabetes 3 questions · 1 source
Specific populations questions that apply to every indication of Trulicity are on Trulicity (dulaglutide), all indications: Specific populations .
Specific populations At what age can children use Trulicity? Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus
Pediatric use How much does Trulicity lower A1C in children 10 and older? Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus
“Table 15: Glycemic Results at Week 26 in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus with Inadequate Glycemic Control Despite Diet and Exercise (With or Without Metformin and/or Basal Insulin)
Abbreviations: HbA1c = hemoglobin A1c.
a Combined results for TRULICITY 0.75 mg and 1.5 mg. The comparison of the two dosages together and individually with placebo was prespecified with overall type I error controlled.
b The change from baseline and difference from placebo were analyzed using analysis of covariance with effects for treatment, the baseline value as a covariate, and stratification factors which were HbA1c at screening (< 8% vs >= 8%), insulin use at baseline (yes/no), metformin use at baseline (yes/no).
c For HbA1c and Fasting Blood Glucose, multiple imputation was performed for missing data guided by washout method. At Week 26 primary efficacy (HbA1c) was missing for 8%, 6%, and 10% of patients on placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg respectively.
d For percentage of patients HbA1c < 7%, missing data was imputed as not achieving the target.
Placebo TRULICITY 0.75 mg once weekly TRULICITY 1.5 mg once weekly TRULICITY once weekly
Pooleda
Intent-to-Treat Population (N) 51 51 52 103
HbA1c (%) (Mean)c
Baseline
Change from baseline at Week 26b
Difference from placebo (95% CI)b 8.1
0.6
- 7.9
-0.6
-1.2 (-1.8, -0.6) 8.2
-0.9
-1.5 (-2.1, -0.9) 8.0
-0.8
-1.4 (-1.9, -0.8)
Percentage of Patients with HbA1c <7.0% at Week 26d 14% 55% 48% 52%
Fasting Blood Glucose (mg/dL) (Mean)c
Baseline
Change from baseline at Week 26b
Difference from placebo (95% CI)b 159
17.1
- 149
-12.8
-29.9 (-50.7, -9.1) 163
-24.9
-42.0 (-63.0, -20.9) 156
-18.9
-35.9 (-54.2, -17.6)” (opens the source at this quote in a new tab) Copy Flag
Note: Table 15 columns are placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and the pooled TRULICITY group. In the HbA1c and fasting blood glucose rows the label lists, for each column in turn, the baseline value, the change from baseline at Week 26, and the difference from placebo.
What are the side effects of Trulicity in children? Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus
“TRULICITY was administered to 150 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 41.3 weeks [see Clinical Studies (14.6)]. The mean age was 14.5 years and 71% of patients were female. Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5 kg and mean BMI was 34.1 kg/m2.” (opens the source at this quote in a new tab) Copy Flag